KANUMA is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.
Alexion Pharmaceuticals, Inc. announced that the European Commission has approved Kanuma (sebelipase alfa) for long-term enzyme replacement therapy in patients...
Alexion Pharmaceuticals, Inc. announced that the European Commission (EC) has approved Kanuma (sebelipase alfa) for long-term enzyme replacement therapy (ERT)...
Alexion Pharmaceuticals, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
Alexion Pharmaceuticals has announced that the FDA has approved Kanuma (sebelipase alfa) for the treatment of patients of all ages...
Synageva has announced that the global, randomized, double-blind, placebo-controlled Phase III ARISE trial of SBC 102 (sebelipase alfa) in 66...
NICE has published draft guidance as part of its highly specialised technologies programme that recommends further clinical trials are carried...
The UK's National Institute for Health and Care Excellence has published its a final evaluation which rejects the use of...
Alexion Pharmaceuticals, Inc. announced that new interim data show that 80% of infants (8 out of 10) with rapidly progressive...